2013-09-25 11:45:03 -
Tokyo, Sept 25, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has been selected for membership of the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).
The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 as the first global SRI indices in the world and each year assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. This year, the DJSI Asia Pacific has selected 152
companies leading the way in sustainability (68 of which are from Japan) from among the region's top 600 companies.
In addition to the DJSI Asia Pacific, Eisai has been selected for the 12th consecutive year since 2002 as a member of the FTSE4Good Global Index, another benchmark SRI index, by FTSE International Limited, which is a subsidiary of the London Stock Exchange.
The Eisai Group's corporate philosophy is to give first thought to patients and their families, and to increase the benefits that health care provides and to address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.
<BR /><BR />Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Contact:Eisai Co., Ltd. +81-(0)3-3817-5120
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net